Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Aurelia Conte

Werner Neidhart

Holger Kuehne

Matthias Heinrich Nettekoven

Daniel Hunziker

Jean Ackermann

Tanja Schulz-Gasch

Stanley Wertheimer

Bernd Kuhn

Ulrike Obst Sander

Simona Maria Ceccarelli

Patrizio Mattei

Hans G Richter

Bernd Buettelmann

Philippe Pflieger

Thomas Luebbers

Werner Mueller

Cyrille Maugeais

Uwe Grether

Jens-Uwe Peters

Henrietta Dehmlow

Robert Narquizian

Markus Rudolph

Fabienne Ricklin

Constantinos G Panousis

Nicole A Kratochwil

Stephan Roever

Stephan Brugger

Constantinos Panousis

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, Rand n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.

Aryl-quinoline derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.

Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, A, A, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.

Bicyclicpyridine derivatives

The invention provides novel compounds having the general formula (I) wherein R, Rand n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.

Azacyclic compounds

The invention provides novel compounds having the general formula (I) wherein R, R, A, E, G and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used for the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds

The invention provides novel compounds having the general formula (I), wherein R, R, Rand A are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used in the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Hexahydropyrroloimidazolone compounds

The invention provides novel compounds having the general formula (I) wherein R, R, Rand A are as described herein, compositions including the compounds and methods of using the compounds.

The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.

HSL inhibitors useful in the treatment of diabetes

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A, A, R, R, Rand Rhave the significance given in claim

Piperidine derivatives

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein R, R, Rand n have the significance given in claim

Azacyclic derivatives

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, m, A, Rand Rhave the significance given in the description. The compounds are useful as HSL inhibitors and may be used in the treatment or prophylaxis of diabetes, dyslipidemia, atherosclerosis or obesity.

The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof, wherein A, A, R, R, R, R, Rand Rhave the significance given herein.

The invention provides novel compounds having the general formula (I) wherein R, Rand A are as described herein, compositions including the compounds and methods of using the compounds. The compounds inhibit hormone sensitive lipase (HSL) and may be used in the treatment of diabetes, metabolic syndrome, and obesity.

Growing community of inventors

Basel, Switzerland

Aurelia Conte